{"nctId":"NCT03643965","briefTitle":"Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy","startDateStruct":{"date":"2018-09-05","type":"ACTUAL"},"conditions":["Primary IgA Nephropathy"],"count":365,"armGroups":[{"label":"Nefecon","type":"EXPERIMENTAL","interventionNames":["Drug: Nefecon"]},{"label":"Placebo oral capsule","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo oral capsule"]}],"interventions":[{"name":"Nefecon","otherNames":["Budesonide modified released capsule"]},{"name":"Placebo oral capsule","otherNames":["Placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Female or male patients ≥18 years\n2. Biopsy-verified IgA nephropathy\n3. Stable dose of RAS inhibitor therapy (ACEIs and/or ARBs) at the maximum allowed dose or Maximum Tolerated Dose (MTD) according to the 2012 KDIGO (Kidney Disease: Improving Global Outcomes) guidelines\n4. Urine protein creatinine ratio ≥1 g/24hr\n5. eGFR ≥35 mL/min per 1.73 m2 and ≤90 mL/min per 1.73 m2 using the Chronic Kidney Diseae Epidemiology Collaboration (CKD-EPI) formula\n6. Willing and able to give informed consent\n\nExclusion Criteria:\n\n1. Systemic diseases that may cause mesangial IgA deposition.\n2. Patients who have undergone a kidney transplant.\n3. Patients with acute or chronic infectious disease including hepatitis, tuberculosis, human immunodeficiency virus (HIV), and chronic urinary tract infections.\n4. Patients with liver cirrhosis, as assessed by the Investigator.\n5. Patients with a diagnosis of type 1 or type 2 diabetes mellitus which is poorly controlled.\n6. Patients with history of unstable angina, class III or IV congestive heart failure, and/or clinically significant arrhythmia, as judged by the Investigator;\n7. Patients with unacceptable blood pressure control defined as a blood pressure consistently above national guidelines for proteinuric renal disease, as assessed by the Investigator\n8. Patients with diagnosed malignancy within the past 5 years.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Part A: Ratio of Urine Protein to Creatinine Ratio (UPCR) at 9 Months Compared to Baseline","description":"Part A primary endpoint: The ratio of Urine Protein to Creatinine Ratio (UPCR) (based on 24-hour urine collections) at 9 months following the first dose of study drug compared to baseline.\n\nRatio being: UPCR at 9 months in g/gram divided with UPCR at Baseline in g/gram","paramType":"GEOMETRIC_LEAST_SQUARES_MEAN","dispersionType":"96% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.69","spread":null},{"groupId":"OG001","value":"0.95","spread":null}]}]}]},{"type":"PRIMARY","title":"Part B: Time-weighted Average of Estimated Glomerular Filtration Rate (eGFR)","description":"Part B Primary endpoint: Time-weighted average of estimated glomerular filtration rate (eGFR) recordings observed at each time point over 2 years. The eGFR (CKD-EPI) at 2 years (which must have been repeated to provide a second value obtained within 14 to 35 days) was the geometric mean of the 2 assessments.","paramType":"GEOMETRIC_LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":null},{"groupId":"OG001","value":"0.87","spread":null}]}]}]},{"type":"SECONDARY","title":"Part A: Ratio of eGFR at 9 Months","description":"Part A: Ratio of eGFR at 9 months compared to baseline calculated using the CKD-EPI formula.","paramType":"GEOMETRIC_LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":null},{"groupId":"OG001","value":"0.93","spread":null}]}]}]},{"type":"SECONDARY","title":"Part A: Ratio of eGFR at 12 Months","description":"Part A: Ratio of eGFR at 12 months compared to baseline calculated using the CKD-EPI formula.","paramType":"GEOMETRIC_LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.97","spread":null},{"groupId":"OG001","value":"0.91","spread":null}]}]}]},{"type":"SECONDARY","title":"Part A: Ratio of Urine Albumin to Creatinine Ratio (UACR) at 9 Months","description":"Part A: Ratio of urine albumin to creatinine ratio (UACR) at 9 months compared to baseline.","paramType":"GEOMETRIC_LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.64","spread":null},{"groupId":"OG001","value":"0.93","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Time to 30% Reduction in eGFR","description":"Part B: Time to 30% reduction from baseline in eGFR (CKD-EPI) confirmed by a second value.\n\nFor clarity: Please note that the number of patients with a 30% reduction is presented with statistical analysis of the time to 30% reduction.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Time to Receiving Rescue Medication.","description":"Part B: Time from the first dose of study drug until receiving rescue medication.\n\nFor clarity: Please note that the number of patients receiving rescue medication is presented with statistical analysis of the time to receiving rescue medication.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Ratio of UPCR Compared to Baseline Averaged Over Time Points Between 12 and 24 Months","description":"Part B: Ratio of UPCR, UACR, and eGFR (CKD-EPI) compared to baseline averaged over time points between 12 and 24 months, inclusive, following the first dose of study drug","paramType":"GEOMETRIC_LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.60","spread":null},{"groupId":"OG001","value":"1.01","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Ratio of UACR Compared to Baseline Averaged Over Time Points Between 12 and 24 Months","description":"Part B: Ratio of UPCR, UACR, and eGFR (CKD-EPI) compared to baseline averaged over time points between 12 and 24 months, inclusive, following the first dose of study drug.","paramType":"GEOMETRIC_LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.52","spread":null},{"groupId":"OG001","value":"0.96","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Ratio of eGFR Compared to Baseline Averaged Over Time Points Between 12 and 24 Months","description":"Part B: Ratio of UPCR, UACR, and eGFR (CKD-EPI) compared to baseline averaged over time points between 12 and 24 months, inclusive, following the first dose of study drug;","paramType":"GEOMETRIC_LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.93","spread":null},{"groupId":"OG001","value":"0.84","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Proportion of Patients Without Microhematuria","description":"Part B: Proportion of patients without microhematuria in at least 2 of the following time points: 12, 18, and 24 months following the first dose of study drug","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Short Form 36 (SF-36) Quality of Life Assessment at 9 Months.","description":"Part B: Short Form 36 (SF-36) quality of life assessment at 9 and 24 months.\n\nThe 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting and have been widely used. It consists of eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions.\n\nHigher scores indicate better health. Scores represent the percentage of total possible score achieved.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.353","spread":"9.0306"},{"groupId":"OG001","value":"54.659","spread":"9.2387"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.058","spread":"9.6373"},{"groupId":"OG001","value":"48.014","spread":"10.0120"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.564","spread":"9.2834"},{"groupId":"OG001","value":"49.760","spread":"8.8974"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.226","spread":"8.9539"},{"groupId":"OG001","value":"50.099","spread":"8.8483"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.257","spread":"7.2188"},{"groupId":"OG001","value":"53.732","spread":"6.5876"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.722","spread":"6.7370"},{"groupId":"OG001","value":"54.276","spread":"5.2243"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.574","spread":"9.4322"},{"groupId":"OG001","value":"50.393","spread":"8.3001"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.028","spread":"8.0207"},{"groupId":"OG001","value":"52.693","spread":"6.6600"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.941","spread":"8.3606"},{"groupId":"OG001","value":"51.707","spread":"7.9259"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.826","spread":"10.0909"},{"groupId":"OG001","value":"53.490","spread":"9.3987"}]}]}]},{"type":"SECONDARY","title":"Part B: Short Form 36 (SF-36) Quality of Life Assessment at 24 Months.","description":"Part B: Short Form 36 (SF-36) quality of life assessment at 9 and 24 months.\n\nThe 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting and have been widely used. It consists of eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions.\n\nHigher scores indicate better health. Scores represent the percentage of total possible score achieved.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.385","spread":"9.6352"},{"groupId":"OG001","value":"53.208","spread":"9.9811"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.038","spread":"9.3450"},{"groupId":"OG001","value":"47.214","spread":"9.9564"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.246","spread":"8.1362"},{"groupId":"OG001","value":"49.743","spread":"10.2184"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.691","spread":"8.2104"},{"groupId":"OG001","value":"50.294","spread":"10.0007"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.443","spread":"7.5200"},{"groupId":"OG001","value":"51.993","spread":"7.1783"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.665","spread":"7.6364"},{"groupId":"OG001","value":"53.059","spread":"6.9006"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.322","spread":"8.4690"},{"groupId":"OG001","value":"49.333","spread":"10.0789"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.948","spread":"7.8921"},{"groupId":"OG001","value":"50.722","spread":"8.8255"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.949","spread":"7.9677"},{"groupId":"OG001","value":"51.471","spread":"8.9304"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.291","spread":"8.8558"},{"groupId":"OG001","value":"52.364","spread":"10.0023"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":18,"n":182},"commonTop":["Nasopharyngitis","Edema peripheral","Headache","Muscle spasms","Hypertension"]}}}